Several immunotherapeutic approaches that exploit the tumor-associated differentiation antigen mesothelin are currently being explored to treat mesothelioma patients, including an anti-mesothelin antibody conjugated with chemotherapy (or not) [38,39] and an immunotoxin-coupled anti-mesothelin antibody variable fragment [40]. Here, MSLN is linked to mesothelioma.